Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 7Phase 2/3 3Phase 1/2 3Phase 1 3

Status

Completed 71Terminated 35Recruiting 23Active not recruiting 12Withdrawn 6Suspended 4Unknown 3Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 2Neoplasm Metastasis 1Leukemia, Myeloid 1Leukemia 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 13Nivolumab 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Radiotherapy 6Cisplatin 6fludarabine phosphate 5Interleukin-2 5Injections 5Doxorubicin 5tislelizumab 4daratumumab 4Paclitaxel 4Ipilimumab 4Immune Checkpoint Inhibitors 4Drug Therapy 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3trastuzumab deruxtecan 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Rituximab 3Radiosurgery 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Azacitidine × Clear all
NCT07548983 2026-04-23

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

OHSU Knight Cancer Institute

Phase 1 Not yet recruiting
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07439211 2026-03-03

GAVEL

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
48 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa

Phase 1 Not yet recruiting
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡